JNJ-78278343 for Prostate Cancer

Phase-Based Progress Estimates
Memorial Sloan Kettering Cancer Center, New York, NYProstate CancerJNJ-78278343 - Drug
What conditions do you have?

Study Summary

This trial is testing a new drug to see what dose is safe and effective.

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

3 Primary · 7 Secondary · Reporting Duration: Up to 1 year and 10 months

Year 1
Duration of Response (DOR)
Number of Participants With Anti-JNJ-78278343 Antibodies
Objective Response Rate (ORR)
PSA Response Rate
Part 1 and 2: Number of Participants With AEs by Severity
Part 1 and 2: Number of Participants With Adverse Events (AEs)
Part 1: Number of Participants With Dose-Limiting Toxicity (DLT)
Serum Concentration of JNJ-78278343
Serum Prostate Specific Antigen (PSA) Concentration
Systemic Cytokine Concentrations

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1

Experimental Treatment

160 Total Participants · 1 Treatment Group

Primary Treatment: JNJ-78278343 · No Placebo Group · Phase 1

Experimental Group · 1 Intervention: JNJ-78278343 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 1 year and 10 months

Who is running the clinical trial?

Janssen Research & Development, LLCLead Sponsor
934 Previous Clinical Trials
6,369,071 Total Patients Enrolled
8 Trials studying Prostate Cancer
2,178 Patients Enrolled for Prostate Cancer
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
717 Previous Clinical Trials
3,951,212 Total Patients Enrolled
7 Trials studying Prostate Cancer
2,688 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 6 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Is enrollment currently open for participation in this trial?

"As reported on, this research endeavour is in the process of sourcing participants. It was posted initially on July 13th 2021 and recently updated on November 22nd 2022." - Anonymous Online Contributor

Unverified Answer

What ultimate effects are investigators hoping to observe with this clinical investigation?

"The principal purpose of this prolonged (over one year and ten months) clinical trial is to determine the occurrence rate of dose-limiting toxicity. Secondary objectives involve measuring serum concentrations of anti-JNJ78278343 antibodies, prostate specific antigen levels, as well as calculating PSA response rates by evaluating any decline from baseline values that are greater than 50%." - Anonymous Online Contributor

Unverified Answer

How many participants have been recruited for this experiment?

"Affirmative. According to the, this medical study is actively recruiting subjects that meet the criteria it posted on July 13 2021 and updated on November 22 2022. The research project requires 110 patients from 3 sites for its completion." - Anonymous Online Contributor

Unverified Answer

What potential risks are posed by JNJ-78278343?

"Due to the limited supporting evidence for JNJ-78278343's efficacy and safety, our team at Power judged it a score 1 on the scale of 1 to 3." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.